Effect of Acute Endurance Exercise on the Production of FGF21 and Follistatin in Patients With Hepatocellular Carcinoma
NCT ID: NCT07189624
Last Updated: 2025-12-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
12 participants
INTERVENTIONAL
2025-12-31
2029-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single arm
A single study visit will be required, during which the following will be caried out:
* an assessment of physical condition: lower limb isometric strength test, liver frailty index, short physical performance battery, ultrasound assessment of quadriceps muscle mass
* a 30-minutes exercise session on a bicycle (with heart rate monitor and gas exchange analyzer)
* 3 fasting blood tests (before, at the end and 1 hour after the exercise) to assess the production of hepatokines and metabolites
* measurements of perceived fatigue, muscle pain and effort (before, at the end and 1 hour after the exercise).
Snacks will be served afterwards.
Exercise
30-minutes exercise on a bicycle with heart rate monitor and gas exchange analyzer.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exercise
30-minutes exercise on a bicycle with heart rate monitor and gas exchange analyzer.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Cirrhosis of any etiology, defined by a liver elasticity measurement \>15kPa or a history of cirrhosis decompensation
* Hepatocellular carcinoma with indication for treatment by immunotherapy or chemoembolization
* Child-Pugh scores A and B7
* WHO score ≤ 2
* Affiliation to french national social security system
Exclusion Criteria
* Bone metastasis
* Surgery performed within 30 days prior to inclusion visit
* Liver transplant
* Muscle injury within 3 months of inclusion
* Pregnant or breast-feeding women
* Patients under legal protection (guardianship, curatorship, safeguard of justice)
* Participation in another clinical trial within 10 days of inclusion
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Estaing Medecine Digestive Et Hepatobiliaire
Clermont-Ferrand, , France
CHU de Clermont-Ferrand
Clermont-Ferrand, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
ARMANDO ABERGEL
Role: primary
lise Laclautre
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RBHP 2024 ABERGEL
Identifier Type: -
Identifier Source: org_study_id